Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG.

Mol Cancer Ther. 2018 Aug;17(8):1739-1751. doi: 10.1158/1535-7163.MCT-17-1095. Epub 2018 May 9.

PMID:
29743205
2.

A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease.

Hatterer E, Shang L, Simonet P, Herren S, Daubeuf B, Teixeira S, Reilly J, Elson G, Nelson R, Gabay C, Sokolove J, McInnes IB, Kosco-Vilbois M, Ferlin W, Monnet E, De Min C.

Arthritis Res Ther. 2016 Oct 6;18(1):224.

3.

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.

Loyau J, Malinge P, Daubeuf B, Shang L, Elson G, Kosco-Vilbois M, Fischer N, Rousseau F.

MAbs. 2014;6(6):1621-30. doi: 10.4161/19420862.2014.975098.

4.

Enhancement of islet engraftment and achievement of long-term islet allograft survival by Toll-like receptor 4 blockade.

Giovannoni L, Muller YD, Lacotte S, Parnaud G, Borot S, Meier RP, Lavallard V, Bédat B, Toso C, Daubeuf B, Elson G, Shang L, Morel P, Kosco-Vilbois M, Bosco D, Berney T.

Transplantation. 2015 Jan;99(1):29-35. doi: 10.1097/TP.0000000000000468.

PMID:
25340601
5.

Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering.

Shang L, Daubeuf B, Triantafilou M, Olden R, Dépis F, Raby AC, Herren S, Dos Santos A, Malinge P, Dunn-Siegrist I, Benmkaddem S, Geinoz A, Magistrelli G, Rousseau F, Buatois V, Salgado-Pires S, Reith W, Monteiro R, Pugin J, Leger O, Ferlin W, Kosco-Vilbois M, Triantafilou K, Elson G.

J Biol Chem. 2014 May 30;289(22):15309-18. doi: 10.1074/jbc.M113.537936. Epub 2014 Apr 15.

6.

Characterization of a surrogate murine antibody to model anti-human CD3 therapies.

Dépis F, Hatterer E, Ballet R, Daubeuf B, Cons L, Glatt S, Reith W, Kosco-Vilbois M, Dean Y.

MAbs. 2013 Jul-Aug;5(4):555-64. doi: 10.4161/mabs.24736. Epub 2013 Apr 18.

7.

Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.

Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N.

J Immunol Methods. 2012 Jan 31;375(1-2):20-9. doi: 10.1016/j.jim.2011.09.002. Epub 2011 Sep 12.

PMID:
21939661
8.

TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice.

Spiller S, Elson G, Ferstl R, Dreher S, Mueller T, Freudenberg M, Daubeuf B, Wagner H, Kirschning CJ.

J Exp Med. 2008 Aug 4;205(8):1747-54. doi: 10.1084/jem.20071990. Epub 2008 Jul 21. Erratum in: J Exp Med. 2008 Sep 1;205(9):2177.

9.

TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock.

Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, Kosco-Vilbois M, Wagner H, Kirschning CJ, Ulevitch R, Elson G.

J Immunol. 2007 Nov 1;179(9):6107-14.

10.

Pivotal involvement of Fcgamma receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1.

Dunn-Siegrist I, Leger O, Daubeuf B, Poitevin Y, Dépis F, Herren S, Kosco-Vilbois M, Dean Y, Pugin J, Elson G.

J Biol Chem. 2007 Nov 30;282(48):34817-27. Epub 2007 Oct 5.

11.

Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria.

Elson G, Dunn-Siegrist I, Daubeuf B, Pugin J.

Blood. 2007 Feb 15;109(4):1574-83. Epub 2006 Oct 12.

12.

Gene expression of Toll-like receptor-2, Toll-like receptor-4, and MD2 is differentially regulated in rabbits with Escherichia coli pneumonia.

Kajikawa O, Frevert CW, Lin SM, Goodman RB, Mongovin SM, Wong V, Ballman K, Daubeuf B, Elson G, Martin TR.

Gene. 2005 Jan 3;344:193-202. Epub 2004 Nov 21.

PMID:
15656985
13.

Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock.

Pugin J, Stern-Voeffray S, Daubeuf B, Matthay MA, Elson G, Dunn-Siegrist I.

Blood. 2004 Dec 15;104(13):4071-9. Epub 2004 Aug 24.

Supplemental Content

Loading ...
Support Center